China-in kum 3 chin vaccine pek phalsak

China chuan emergency-a naupang pek atan Sinovac Biotech coronavirus vaccine hman phalna pe a, kum thum chunglamin vaccine hi an la thei dawn a ni. Tun thleng hian an ramah kum 18 leh a chunglam tan chuah vaccine hi semchhuah a la ni.

Company chairman Yin Weidong chuan Zirtawpni khan sorkar thutlukna siam chungchang hi a tichhuak a ni. Mahse sorkar hian naupang tana vaccine pekchhuah kalpui ṭan hun tur erawh a la puang lo.

Phase 1 leh 2 clinical trial result-ah he vaccine hian puitlinga a thawh ang bawkin natna dona kawngah naupang a ṭanpui theih thu leh an taksa-ah a harsatna a siam nasat loh thu tarlan a ni.

Sinovac vaccine hi vaccine dang ang thoin vawi hnih an lak hnuah vawi thumna atan booster pek an ni. Kar khat hnuah an taksaa natna dotute chu a let sawma pungin, thla chanve hnuah chuan a let 20 vela a pun thu Yin chuan a sawi.

Damdawi siamtu company dang, Sinopharm pawhin an vaccine siam chu naupangte tana hman phalsak dilna sorkar hnenah an thehlut tawh bawk. CanSino Biologics' siam vaccine chu naupang kum 6-17 inkarah enchhinin, clinical trial phase II neih mek a ni bawk.

China ramah hian vaccine pek runpui kalpui mek niin, ni nga chhung lekin mi maktaduai 100 hnenah pek an ni. China public health official-te chuan an ram mipui, tluklehdingawn 1.4 zingah 80% chu kumin chhungin vaccine hi pek hman an tum tih sawiin, nimin thleng khan vaccine hi dose maktaduai 763 pek chhuah a ni tawh a ni, an ti.

World Health Organisation (WHO) chuan June 1 khan Sinovac vaccine hi a pawmsak a, a hmain Sihopharm vaccine pawh a lo pawm tawh bawk. China chuan an rama hman turin Covid vaccine hi panga a pawm tawh thung.